Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

• The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares traded as high as 5.26 percent, in a range of $1.9 to $2 on day volume of 111.77 thousand shares, closed regular trading session at $1.9.

• Centessa Pharmaceuticals (NASDAQ:CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B. Centessa shares traded as high as 10.56 percent, in a range of $4.09 to $4.71 on day volume of 180.95 thousand shares, closed regular trading session at $4.64.